The association between anti-insulin aspart antibodies and the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in children and adolescents with type 1 diabetes.
Torben BiesterThekla von dem BergeLine Quist BendtsenMette Dahl BendtsenNaveen RathorThomas DanneHanne HaahrPublished in: Pediatric diabetes (2020)
In children and adolescents with T1D, faster aspart provides ultrafast pharmacokinetics irrespective of free or total IAsp assay. Elevated anti-IAsp antibodies are associated with higher total IAsp concentration, but do not impact faster aspart and IAsp glucose-lowering effect.